Trials / Unknown
UnknownNCT03027739
CART-19 Cells For MRD Positive CD19+ ALL
CART-19 Cells For Patients With Minimal Residual Disease (MRD) Positive CD19+ Acute Lymphoblastic Leukemia
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 1 Year – 60 Years
- Healthy volunteers
- Not accepted
Summary
CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CART-19 | CART-19 cells treated |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2019-12-01
- Completion
- 2020-12-01
- First posted
- 2017-01-23
- Last updated
- 2017-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03027739. Inclusion in this directory is not an endorsement.